Sanofi Consumer Healthcare India Reports 21% Revenue Growth in FY 2025
Filing Summary
Sanofi Consumer Healthcare India Limited announced its audited financial results for the quarter and fiscal year ending December 31, 2025. The company reported a 21% increase in annual revenue, reaching ₹8,784 million, and a 33% rise in net profit, totaling ₹2,401 million. For Q4 2025, revenue grew by 47% to ₹2,510 million, with a net profit increase of 50% to ₹665 million. Domestic sales rose by 23%, while export sales surged by 158% for the year. A dividend of ₹75 per share was declared.
Sanofi Consumer Healthcare India Limited has released its audited financial results for the quarter and fiscal year ending December 31, 2025. The Board of Directors approved the financial statements during their meeting on February 25, 2026. The company reported significant growth in both quarterly and annual financial metrics.
For the fourth quarter of 2025, revenue was ₹2,510 million, marking a 47% increase compared to the same period in the previous year. The net profit for the quarter was ₹665 million, reflecting a 50% year-on-year growth. On an annual basis, the company achieved a revenue of ₹8,784 million, up by 21% from the previous year. The net profit for the fiscal year was ₹2,401 million, representing a 33% increase. The company declared a dividend of ₹75 per share for the year ended December 31, 2025.
Operationally, the company experienced a 23% growth in domestic sales for the fourth quarter. Export sales saw a substantial increase, growing by 9.3 times due to a low base effect. For the full year, domestic sales grew by 7%, while export sales increased by 158%, again attributed to a low base. The company attributed its financial performance to disciplined cost management and an improved product mix.
The company operates in the Consumer Healthcare sector, focusing on products related to Allergy, Digestive Wellness, Pain Care, and Multivitamins. Key brands include Allegra®, DePURA®, Avil®, and Combiflam®. The company emerged as a distinct legal entity following its demerger from Sanofi India Limited on June 1, 2024.
The financial results were announced on February 25, 2026, with the Board of Directors meeting held on the same day. The company operates from its headquarters in Mumbai, Maharashtra, and is listed on both the BSE and NSE under the symbols 544250 and SANOFICONR, respectively.
Sanofi Consumer Healthcare India Limited focuses on enhancing customer wellbeing through its portfolio of consumer healthcare products. The company aims to empower individuals to take control of their health by addressing everyday health concerns. It leverages its global experience in consumer healthcare to maintain a strong presence in the Indian market.